Compare Incyte Corporation (INCY) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Msci Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Msci Inc trades at $555 (market cap $45.51B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays a 1.31% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MSCI | |
|---|---|---|
Market Cap | $23.11B | $45.51B |
Sector | Health | Financials |
52-Week High | $118.52 | $643.83 |
52-Week Low | $67.38 | $511.84 |
Enterprise Value | $19.13B | $51.67B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MSCI trades at $625.11, down 0.56% on the day, with a bullish technical outlook supported by moving averages and a recent strategic partnership with UBS to enhance its private markets platform. The company shows strong fundamentals with a 40.74% net income margin and consistent earnings beats, though valuation ratios like a P/E of 35.9 suggest a premium. Analyst consensus is strongly bullish with a $723.38 price target, and cash flow turned positive in 2025 after prior years of net outflows.
The outlook for MSCI is positive, driven by earnings growth, high profitability, and strategic expansions, but risks include elevated debt levels and sensitivity to financial market conditions. The stock offers a dividend yield supported by solid cash generation, though investors should weigh the high valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
